Save Product
Product Details
Synonyms
IL-15, Interleukin-15, MGC9721
Source
Biotinylated Human IL-15, His,Avitag (IL5-H82E3) is expressed from human 293 cells (HEK293). It contains AA Asn 49 - Ser 162 (Accession # P40933-1).
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 16.5 kDa. The protein migrates as 22-27 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Biotinylated Human IL-15, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-ELISA
Immobilized Human IL-15 R alpha, Fc Tag (Cat. No. ILA-H5253) at 2 μg/mL (100 μL/well) can bind Biotinylated Human IL-15, His,Avitag (Cat. No. IL5-H82E3) with a linear range of 0.2-8 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Interleukin-15
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
29 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
